{"title":"The clinical promise of 18F-flurpiridaz PET imaging heralds a new frontier in the diagnosis and management of coronary artery disease","authors":"René R. Sevag Packard","doi":"10.1038/s44161-024-00587-w","DOIUrl":null,"url":null,"abstract":"The PET radiotracer 18F-flurpiridaz has undergone rigorous clinical testing and gained FDA approval for the evaluation of coronary artery disease. Its unique properties suggest 18F-flurpiridaz has the potential to transform the field of nuclear myocardial perfusion imaging and blood flow quantification, with far-reaching effects on cardiovascular care.","PeriodicalId":74245,"journal":{"name":"Nature cardiovascular research","volume":"4 1","pages":"1-4"},"PeriodicalIF":10.8000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cardiovascular research","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44161-024-00587-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
The PET radiotracer 18F-flurpiridaz has undergone rigorous clinical testing and gained FDA approval for the evaluation of coronary artery disease. Its unique properties suggest 18F-flurpiridaz has the potential to transform the field of nuclear myocardial perfusion imaging and blood flow quantification, with far-reaching effects on cardiovascular care.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
